Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant lymphoma idiotype vaccine
- Development stage
- Phase 2
- Lead developer
- Universitätsklinikum Freiburg
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intradermal
01
Overview
The recombinant lymphoma idiotype vaccine is an individualized **therapeutic cancer vaccine** developed at University Medical Center Freiburg for indolent B-cell lymphomas. Each patient-specific product contains recombinant Fab fragments representing the variable-region idiotype of the malignant B-cell clone's surface immunoglobulin, produced in *Escherichia coli*. Intradermal vaccination with adjuvanted recombinant Fab protein is intended to induce idiotype-specific humoral and T-cell immune responses against lymphoma cells; granulocyte-macrophage colony-stimulating factor was co-administered subcutaneously as an immune adjuvant in clinical studies. The program was evaluated in Phase I advanced B-cell lymphoma and Phase II indolent B-cell lymphoma studies, including follicular lymphoma.
- Other names
- Fab IdIdvaxIIrecombinant idiotype Fab fragment vaccine
02
Targets
Id (Tumor-specific idiotype immunoglobulin)
Beyond the preview
Go deeper on recombinant lymphoma idiotype vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant lymphoma idiotype vaccine.